| RNA | Ribo-Nucleic Acid |
|---|---|
| HARS | histidyl-RNA synthetase |
| poly-IC, | poly-I:C copolymer of polyinosinic and polycytidylic acids; synthetic RNA polymer |
| RNA | radionuclide angiography; Registered Nurse Anesthetist; ribonucleic acid; rough, noncapsulated, avir... |
| U-RNA | uridylic acid ribonucleic acid |
| 5' SS | 5' splice site |
|---|---|
| D RNA | defective RNA |
| HCV RNA | Hepatitis C virus RNA |
| hn-RNA | Heteronuclear RNA |
| I-RNA | Immune RNA |
| donor splice junction | <molecular biology> The junction between an exon and an intron at the 5' end of the intron. When the intron is removed during processing of hnRNA the donor junction is spliced to the acceptor junction at the 3' end of the intron. (15 Nov 1997) |
|---|---|
| attachment sites | <microbiology, molecular biology> Particular loci in both bacterial and phage DNA molecules at which phage DNA is integrated into the bacterial DNA by recombination between these sites. (12 Dec 1998) |
| binding sites | The reactive parts of a macromolecule that directly participate in its specific combination with another molecule. (12 Dec 1998) |
| binding sites, antibody | Local surface sites on antibodies which react with antigen determinant sites on antigens. They are formed from parts of the variable regions of the fab fragment of the immunoglobulin. (12 Dec 1998) |
| chromosome fragile sites | Heritable sensitive regions of chromosomes which show up in vitro as non-staining bands. They are associated with chromosome breakage and other aberrations, and, when located on sex chromosomes, they produce phenotypic abnormalities. No abnormal phenotype has been definitely identified with autosomal fragile sites, but some rare autosomal recessive disorders may be due to homozygosity for fragile sites. Fragile sites are designated by the letters "fra" followed by the designation for the specific chromosome and locus. (12 Dec 1998) |
| contact sites A | Developmentally regulated adhesion sites that appear on the ends of aggregation competent Dictyostelium discoideum at the stage when the starved cells begin to come together to form the grex. Originally detected by the use of Fab fragments of polyclonal antibodies, raised against aggregation competent cells and adsorbed against vegetative cells, to block adhesion in EDTA containing medium. (Cell cell adhesion mediated by contact sites A, unlike that mediated by contact sites B, is not divalent cation sensitive). The fact that a mutant deficient in csA behaves perfectly normally in culture is puzzling. (18 Nov 1997) |
| contact sites B | Developmentally regulated adhesion sites that appear on the ends of aggregation competent Dictyostelium discoideum at the stage when the starved cells begin to come together to form the grex. Originally detected by the use of Fab fragments of polyclonal antibodies, raised against aggregation competent cells and adsorbed against vegetative cells, to block adhesion in EDTA containing medium. (Cell cell adhesion mediated by contact sites A, unlike that mediated by contact sites B, is not divalent cation sensitive). The fact that a mutant deficient in csA behaves perfectly normally in culture is puzzling. (18 Nov 1997) |
| crohn disease: sites | <radiology> Oesophagus: rare, stomach (2-20%): granulomatous gastritis, pseudo-post Bilroth-I appearance, ramshorn sign, antral-duodenal fistula, duodenum (4-10%): almost always associated with gastric involvement, bulb and proximal half of duodenum, small bowel (80%): regional enteritis, terminal ileum (alone/in combination): 95%, jejunum/ileum: 15%, commonly associated with medial caecal defect, colon (22-55%): granulomatous colitis, particularly on the right side, transverse stripe sign: contrast within coarse mucosal folds, rectum (35-50%) see: Crohn disease (12 Dec 1998) |
| sequence tagged sites | Short, tagged tracts of DNA sequence that are used as landmarks in genome mapping. In most instances, 200 to 500 base pairs of sequence define a sequence tagged site (sts) that is operationally unique in the human genome (i.e., can be specifically detected by the polymerase chain reaction in the presence of all other genomic sequences). The overwhelming advantage of stss over mapping landmarks defined in other ways is that the means of testing for the presence of a particular sts can be completely described as information in a database. (12 Dec 1998) |
| sequence-tagged sites | Short stretches of DNA sequences that can be detected by use of the polymerase chain reaction. (05 Mar 2000) |
| immunologically privileged sites | Sites where allografts are not readily rejected, probably because these particular areas have poor lymphatic drainage. (05 Mar 2000) |
| acceptor RNA | rNA |
| antisense RNA | <molecular biology> A complementary RNA sequence that binds to (and thus blocks the transcription of) a naturally-occuring (sense) messenger RNA molecule. These proteins can be used to selectively turn off production of certain proteins or block viral genetic instructions, by marking them for destruction by cellular enzymes, in order to prevent the building of new virus or the infection of new cells. (09 Oct 1997) |
| bacteriophage T3 RNA polymerase | <enzyme> Used for the rapid generation of strand-specific RNA molecules that can be used for the identification of genes in hybridization experiments Registry number: EC 2.7.7.- Synonym: t3 RNA polymerase (26 Jun 1999) |
| cap II RNA(nucleoside-2'-)methyltransferase | <enzyme> Converts cap i-terminated mRNA to cap II-terminated mRNA Registry number: EC 2.1.1.- Synonym: cap II methylase (26 Jun 1999) |
Synonyms : 3' Splice Site, 5' Splice Site, Alternative Splice Sites, Cryptic Splice Sites, 3' Splice Sites, 5' Splice Sites, Acceptor Site, Splice, Acceptor Sites, Splice, Alternative Splice Site, Cryptic Splice Site, Donor Site, Splice, Donor Sites, Splice, Splice Site, 3'
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|